- Home
- RNXT vs GSIW Comparison
RNXT vs GSIW Comparison
Compare RNXT & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNXT | GSIW |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 33.5M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RNXT | GSIW |
|---|---|---|
| Price | $0.95 | $29.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.25 | N/A |
| AVG Volume (30 Days) | ★ 221.2K | 4.4K |
| Earning Date | 05-14-2026 | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,123,000.00 | N/A |
| Revenue This Year | $194.66 | N/A |
| Revenue Next Year | $279.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | N/A |
| 52 Week Low | $0.70 | $0.05 |
| 52 Week High | $1.45 | $38.55 |
Technical Indicators
Market Signals| Indicator | RNXT | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 51.29 |
| Support Level | $0.81 | $26.25 |
| Resistance Level | $0.98 | $32.67 |
| Average True Range (ATR) | 0.05 | 2.30 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 61.53 | 26.29 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.